SpringWorks Therapeutics (SWTX) announced that the Company anticipates the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, will adopt an opinion on the marketing authorization application, MAA, for nirogacestat, an oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors in the second quarter of 2025
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWTX:
- BofA moves to No Rating on SpringWorks Therapeutics
- M&A News: Merck KGaA to Buy SpringWorks for $3.5B to Boost Oncology Business
- Merck KGaA confirms late-stage talks to acquire SpringWorks for $47 per share
- Merck KGaA near $47 per share deal to buy SpringWorks Therapeutics, WSJ says
- SpringWorks EU approval would enhance strategic value, says Evercore